0 projects

Date from new to old

PES2020-Prosj.etabl.støtte H2020

A clinical phase I/II trial for the vaccine Vacc-C5 in HIV patients.

Bionor currently has two vaccines in clinical development (Vacc-4x and Vacc-C5) for functional HIV cure; i.e. leading to long-term remission of HIV infection in the absence of antiretroviral therapy (ART), the state-of-the art treatment for HIV today. A functional cure will provide a new paradigm...

Awarded: NOK 74,999

Project Period: 2018-2019

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

Clinical phase I/II program for Vacc-C5 and Vacc-4x as a combined immune stimulatory therapy for individuals with HIV.

Bionor currently has two vaccines in clinical development (Vacc-4x and Vacc-C5) and the aim is to develop a functional HIV cure; i.e. leading to long-term remission of HIV infection in the absence of antiretroviral therapy (ART), the state-of-the art treatment for HIV today. The presence of Ab...

Awarded: NOK 99,999

Project Period: 2018-2019

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

A clinical phase 1/2 programme for Vacc-C5 as a component of functional HIV cure.

Awarded: NOK 99,999

Project Period: 2018-2019

Location: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Towards a functional Cure for HIV: Combining reservoir purging agent (HDACi) with therapeutic vaccination (Vacc-4x)- The REDUC Study.

Infeksjon med humant immunsvikt virus (HIV)-1 truer fortsatt den globale helsen. I 2015 var det 36.7 millioner mennesker som levde med HIV-1 på verdensbasis. HIV-infeksjon behandles med en kombinasjon av antiretrovirale midler (ART) som kan redusere virusmengden i blodet til under deteksjonsnivå....

Awarded: NOK 16.6 mill.

Project Period: 2014-2017

Location: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Vacc-HIV: A novel therapeutic vaccine combination for HIV infection

Livslang kombinert antiretroviral behandling (ART) representerer gullstandarden for behandling av humant immunsvikt virus (HIV) infeksjon. Siden 2013 har retningslinjene for HIV behandling anbefalt at ART medisin gis til alle som lever med HIV uansett deres CD4 tall (immunstatus). I 2012 fikk 9.7...

Awarded: NOK 6.3 mill.

Project Period: 2013-2016

Location: Oslo

GLOBVAC-Global helse- og vaksin.forskn

Towards Eradication of HIV-1: Therapeutic Vaccination with the peptide-based candidate Vacc-4x

Vacc-4x Reboost studien (NCT01712256) var en videreføring av den store fase II kliniske studien (NCT00659789) der den peptid-baserte terapeutiske HIV vaksinekandidaten, Vacc-4x, induserte en statistisk signifikant reduksjon i virusmengde (set-point) sammenlignet med placebo etter at antiretrovira...

Awarded: NOK 6.4 mill.

Project Period: 2012-2018

Location: Oslo

GLOBHELS-Global helse

Studies to complete the phase II clinical stage of development for the peptide-based HIV-1 therapeutic vaccine candidate Vacc-4x.

Combination antiretroviral therapy (ART) for HIV infection has improved the longevity of infected individuals and as new infections occur each year, the overall number in need of ART is rising increasing the financial burden for healthcare services. ART l imitations include increasing multidrug r...

Awarded: NOK 7.5 mill.

Project Period: 2009-2012

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

Development of a peptide-based therapeutic vaccine to combat HIV disease (chronic immune stimulation)

This project aims to develop a novel therapeutic vaccine that induces nonneutralising antibodies to human immunodeficiency virus (HIV) to modulate disease rather than inhibit infection. Much evidence has now accumulated supporting the concept that acquire d immunodeficiency syndrome (AIDS) is an ...

Awarded: NOK 7.9 mill.

Project Period: 2008-2011

Location: Oslo

GLOBHELS-Global helse

Phase IIb-Test of Concept Clinical Trial of the Peptide-based HIV-1 Therapeutic Vaccine Candidate Vacc-4x

Combination antiretroviral therapy (ART), the daily life long treatment for human immunodeficiency virus (HIV) infection is costly and associated with adverse side effects following long term use (e.g. metabolic toxicity). This study will further the cli nical development of the peptide-based HI...

Awarded: NOK 5.0 mill.

Project Period: 2008-2009

Location: Oslo

FUGE-Funksjonell genomforskn.i Norg

Development of a Peptide-based Universal Influenza Vaccine

This study aims to develop a safe and effective peptide-based universal influenza vaccine targeting dendritic cells, that stimulates cell mediated immunity to reduce morbidity and mortality associated with influenza virus infection. Such a vaccine can be made in advance of a pandemic and can also...

Awarded: NOK 8.2 mill.

Project Period: 2006-2010

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

Advances in peptide design and laboratory testing to identify suitable peptide-based HIV immunotherapy candidates for product development

The objective of this project is to analyse and select a range of immunogenic peptides as candidate HIV immunotherapies for future human clinical trials. Immunotherapy strategies are needed to counteract both the financial and physical burdens of current HIV drugs on human health. Drug-resistant ...

Awarded: NOK 5.8 mill.

Project Period: 2006-2008

Location: Oslo

PES-EU-Prosjektetablererstøtte EU (bedrift)

Enhancing efficiency of HIV-1, hepatitis and cancer therapeutic treatment by significantly increasing the accuracy of peptide drug deliv....

...

Awarded: NOK 0.12 mill.

Project Period: 2004-2007

Location: Oslo

PES-EU-Prosjektetablererstøtte EU (bedrift)

Prosjektetablering i forbindelse med EU-søknad ang. ny peptidbasert immunterapi for HIV-smittede

...

Awarded: NOK 50,999

Project Period: 2004-2004

Location: Oslo

PROSBIO-Prosess- og biomedisinsk industri

Immunterapi for behandling av HIV-positive pasienter

De siste årene har det blitt betydelig fokus på mulighetene for bruk av immunterapeutiske metoder i behandling av ulike sykdomstilstander. Oppmerksomheten har først og fremst vært rettet mot behandling av kreft, men HIV har også blitt mer og mer aktuell. Det fins mange former for immunterapi. Vår...

Awarded: NOK 4.5 mill.

Project Period: 2001-2004

Location: Oslo